Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Cisplatin and ultra-violet-C synergistically down-regulate receptor tyrosine kinases in human colorectal cancer cells.

Kawaguchi J, Adachi S, Yasuda I, Yamauchi T, Nakashima M, Ohno T, Shimizu M, Yoshioka T, Itani M, Kozawa O, Moriwaki H.

Mol Cancer. 2012 Jul 12;11:45. doi: 10.1186/1476-4598-11-45.

2.

Ultraviolet irradiation can induce evasion of colon cancer cells from stimulation of epidermal growth factor.

Adachi S, Yasuda I, Nakashima M, Yamauchi T, Kawaguchi J, Shimizu M, Itani M, Nakamura M, Nishii Y, Yoshioka T, Hirose Y, Okano Y, Moriwaki H, Kozawa O.

J Biol Chem. 2011 Jul 22;286(29):26178-87. doi: 10.1074/jbc.M111.240630. Epub 2011 Jun 6.

3.

Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.

Takaoka S, Iwase M, Uchida M, Yoshiba S, Kondo G, Watanabe H, Ohashi M, Nagumo M, Shintani S.

Int J Oncol. 2007 Jun;30(6):1469-76.

PMID:
17487368
4.

Ultra-violet irradiation induces apoptosis via mitochondrial pathway in pancreatic cancer cells.

Yamauchi T, Adachi S, Yasuda I, Nakashima M, Kawaguchi J, Yoshioka T, Hirose Y, Kozawa O, Moriwaki H.

Int J Oncol. 2011 Dec;39(6):1375-80. doi: 10.3892/ijo.2011.1188. Epub 2011 Sep 5.

PMID:
21894434
5.

Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.

Kim SH, Song YC, Kim SH, Jo H, Song YS.

Ann N Y Acad Sci. 2009 Aug;1171:642-8. doi: 10.1111/j.1749-6632.2009.04893.x.

PMID:
19723115
6.

[Effect of gefitinib on radiosensitivity of gastric cancer cell lines].

Cao WG, Ma T, Li JF, Li H, Ji YB, Chen XH, Liu BY, Jin YN.

Ai Zheng. 2007 Dec;26(12):1330-5. Chinese.

PMID:
18076795
8.

Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.

Michaelis M, Bliss J, Arnold SC, Hinsch N, Rothweiler F, Deubzer HE, Witt O, Langer K, Doerr HW, Wels WS, Cinatl J Jr.

Clin Cancer Res. 2008 Oct 15;14(20):6531-7. doi: 10.1158/1078-0432.CCR-08-0821.

9.

Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.

Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB, Johnston PG.

Mol Cancer Ther. 2006 May;5(5):1154-65.

10.

STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.

Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM.

Laryngoscope. 2006 Aug;116(8):1409-16.

PMID:
16885745
11.

Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.

Guo XF, Zhu XF, Zhong GS, Deng BG, Gao ZT, Wang H.

Oncol Rep. 2012 May;27(5):1639-45. doi: 10.3892/or.2012.1659. Epub 2012 Jan 26.

PMID:
22293713
12.

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G.

Clin Cancer Res. 2000 May;6(5):2053-63.

13.

Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule.

Heravi M, Rachid Z, Goudarzi A, Schlisser A, Jean-Claude BJ, Radzioch D, Muanza TM.

Anticancer Drugs. 2009 Sep;20(8):659-67. doi: 10.1097/CAD.0b013e32832cb8bc.

PMID:
19581798
14.

Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA.

Dixit M, Yang JL, Poirier MC, Price JO, Andrews PA, Arteaga CL.

J Natl Cancer Inst. 1997 Mar 5;89(5):365-73.

PMID:
9060958
15.

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.

Exp Cell Res. 2005 Apr 1;304(2):604-19. Epub 2005 Jan 21.

PMID:
15748904
16.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

18.

Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.

Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, Johnston P.

Clin Cancer Res. 2005 Oct 15;11(20):7480-9.

19.

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.

Qi W, Cooke LS, Stejskal A, Riley C, Croce KD, Saldanha JW, Bearss D, Mahadevan D.

BMC Cancer. 2009 May 11;9:142. doi: 10.1186/1471-2407-9-142.

20.

Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.

Ohta T, Ohmichi M, Shibuya T, Takahashi T, Tsutsumi S, Takahashi K, Kurachi H.

Cancer Biol Ther. 2012 Apr;13(6):408-16. doi: 10.4161/cbt.19292. Epub 2012 Apr 1.

PMID:
22313686

Supplemental Content

Support Center